MONTREAL, QUEBEC -- (MARKET WIRE) -- September 19, 2006 -- Ecopia BioSciences Inc. (TSX: EIA) announced today that it has received a No Objection Letter from the Therapeutics Products Directorate of Health Canada for the amendment to the ongoing Phase I clinical trial related to the Company's anticancer agent, ECO-4601, allowing for the inclusion of pancreatic cancer patients. This selective inclusion of pancreatic cancer patients is consistent with Ecopia's clinical plans to focus on fast track opportunities, including glioma.
